Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with Type 2 diabetes mellitus

Background Both HMG‐CoA reductase inhibitors and fibric acid derivates are used for the treatment of dyslipidemia in Type 2 diabetes patients. The aim of this study was to compare the lipid lowering effect of 40 mg pravastatin, a HMG‐CoA reductase inhibitor, and 400 mg bezafibrate, a fibric acid der...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes/metabolism research and reviews 2000-03, Vol.16 (2), p.82-87
Hauptverfasser:	Rustemeijer, C., Schouten, J. A., Voerman, H. J., Hensgens, H. E. S. J., Donker, A. J. M., Heine, R. J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Anticholesteremic Agents - therapeutic use bezafibrate Bezafibrate - therapeutic use Biological and medical sciences Cholesterol - blood Cholesterol, HDL - blood Cholesterol, LDL - blood Cholesterol, VLDL - blood Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Female General and cellular metabolism. Vitamins Humans Hyperlipidemias - blood Hyperlipidemias - complications Hyperlipidemias - drug therapy Hypolipidemic Agents - therapeutic use Insulin - therapeutic use lipids lipoprotein composition Male Medical sciences Middle Aged Pharmacology. Drug treatments pravastatin Pravastatin - therapeutic use Triglycerides - blood Type 2 diabetes mellitus (DM)
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!